Drug Safety Review Needs Continued Input From OND Experts – Woodcock
This article was originally published in The Tan Sheet
Executive Summary
The potential for an independent drug safety office to cut off medical experts from postmarket review would be a major drawback to the proposal, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD